COMPARISON
Glucagon vs Semaglutide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Glucagon is authorised or registered in 10 and Semaglutide in 10 of the 10 registers read. Glucagon: highest phase Phase 4 (after approval). Semaglutide: highest phase Phase 4 (after approval). 159 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Glucagon | Semaglutide | |
|---|---|---|
| Registered trials differs | 1514 clinicaltrials.gov · 2026-10-03 | 861 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Glucagon openfda · 2026-10-03T17:23:44.062Z | FDA-approved: OZEMPIC openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2019-12-16 ema · 2026-10-03 | 2018-02-08 ema · 2026-10-03 |
| ATC code differs | H04AA01 ema · 2026-10-03 | A10BJ06 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Glucagon | placebo | Semaglutide | placebo |
|---|---|---|---|---|
| Nausea | - | - | 19.5% | 4.5% |
| COVID-19 | - | - | 17.0% | 17.8% |
| Diarrhoea | - | - | 11.8% | 4.5% |
| Constipation | - | - | 8.9% | 2.8% |
| Vomiting | - | - | 8.6% | 1.6% |
| Nasopharyngitis | - | - | 7.5% | 6.1% |
| Decreased appetite | - | - | 6.3% | 1.3% |
| Dyspepsia | - | - | 5.3% | 1.2% |
| Headache | - | - | 4.0% | 2.1% |
| Upper respiratory tract infection | - | - | 2.7% | 1.9% |
Trial register Glucagon: 2 placebo-controlled trials; Semaglutide: 50. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Glucagon side effects · Semaglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Glucagon | Semaglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
159 registered trials include both
| NCT05254314 | Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) ACTIVE_NOT_RECRUITING · updated 2026-10-01 |
|---|---|
| NCT07249554 | Combination Therapy for Alcohol Use Disorder NOT_YET_RECRUITING · updated 2026-10-01 |
| NCT06738979 | A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects COMPLETED · updated 2026-09-25 |
| NCT07511543 | Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy NOT_YET_RECRUITING · updated 2026-09-24 |
| NCT06779929 | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes COMPLETED · updated 2026-09-18 |
| NCT07169136 | Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) RECRUITING · updated 2026-09-18 |
| NCT06836284 | The Evira Study: Additional Support During Obesity Treatment RECRUITING · updated 2026-09-10 |
| NCT05202353 | A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver ACTIVE_NOT_RECRUITING · updated 2026-09-09 |
| NCT06534411 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGL COMPLETED · updated 2026-09-09 |
| NCT06221969 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With COMPLETED · updated 2026-09-04 |
| NCT07446998 | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss ACTIVE_NOT_RECRUITING · updated 2026-09-04 |
| NCT06803888 | Bariatric Surgery vs. Semaglutide vs. Tirzepatide ACTIVE_NOT_RECRUITING · updated 2026-09-03 |
| NCT06762314 | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes COMPLETED · updated 2026-09-02 |
| NCT07284979 | Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes RECRUITING · updated 2026-09-01 |
| NCT06548490 | GLP-1R Agonist Treatment for Opioid Use Disorder RECRUITING · updated 2026-08-28 |
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry NOT_YET_RECRUITING · updated 2026-08-26 |
| 2024-518682-95-00 | SIGNAL - Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes Not stated · updated 2026-08-20 |
| NCT06546384 | GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease NOT_YET_RECRUITING · updated 2026-08-19 |
| NCT06807970 | Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist ACTIVE_NOT_RECRUITING · updated 2026-08-19 |
| NCT07770152 | Semaglutide in Youth With Autism Spectrum Disorder NOT_YET_RECRUITING · updated 2026-08-18 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.